Parkinson
1. Thaler A., Mirelman A., Gurevich T., Simon E., Orr-Urtreger A., Marder K.S., Bressman S., Giladi N.
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers
Neurology Sep 4;79(10):1027-1032.
2. Van Nuenen BF, Helmich RC, Ferraye M, Thaler A, Hendler T, Orr-Urtreger A, Mirelman A, Bressman S, Marder KS, Giladi N, van de Warrenburg BP, Bloem BR, Toni I; on behalf of the LRRK2 Ashkenazi Jewish Consortiu.
Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
Brain. 2012 Dec;135(Pt 12):3687-3698.
3. Rosenberg Katz K., Herman T., Jacob Y., Giladi N., Hendler T., Hausdorff J.M.
Gray matter atrophy distinguishes between Parkinson Disease motor subtypes
Neurology, 2013;80:1–9.
4. Gan-Or Z, Ozelius LJ, Bar-Shira A, Saunders-Pullman R, Mirelman A, Kornreich R, Gana- Weisz M, Raymond D, Rozenkrantz L, Deik A, Gurevich T, Gross SJ, Schreiber-Agus N, Giladi N, Bressman SB, Orr-Urtreger A.
The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinsons' disease.
Neurology. 2013 Apr 23;80(17):1606-10.
5. Plotnik M., Shama S., Brozgol M., Dorfman M., Gazit E., Giladi N., Hausdorff J.M.
A motor learning based intervention to ameliorate freezing of gait in subjects with Parkinson's disease
J Neurol. 2014 Apr 23
Genetics:
6. A. Orr-Utreger, C. Shifrin, U. Rozovsky, S. Rosner, D. Berkovich, T Gurevich, H Yagev More, A. Bar Shira, N. Giladi.
The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinsons disease is there a gender effect?
Neurology 69(16):1595-1602; 2007.
IF= 8.017. Rank in category: Clinical Neurology= 4/185
7. E Sidransky, MA Nalls, JO Aasly, J. Aharon-Peretz , G. Annesi, ER Barbosa, A. Bar-Shira, D.Berg, J. Bras, A. Brice, CM.Chen, LN. Clark, C. Condroyer, EV. De Marco, A. Dürr, MJ. Eblan, S. Fahn, MJ. Farrer, HC. Fung, Z. Gan-Or, T. Gasser, R. Gershoni-Baruch, N. Giladi, A. Griffith, T. Gurevich, C. Januario, P. Kropp, AE. Lang, GJ. Lee-Chen, S. Lesage, K. Marder, IF. Mata, A. Mirelman, J. Mitsui, I Mizuta, G. Nicoletti, C. Oliveira, R. Ottman, A. Orr-Urtreger, LV. Pereira, A. Quattrone, E. Rogaeva, A. Rolfs, H. Rosenbaum, R. Rozenberg, A. Samii, T. Samaddar, C. Schulte, M. Sharma, A. Singleton, M. Spitz, EK. Tan, N. Tayebi, T. Toda, AR. Troiano, S. Tsuji, M. Wittstock, TG. Wolfsberg, YR. Wu, CP. Zabetian, Y. Zhao, SG. Ziegler.
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.
N Engl J Med; 361(17):1651-61; 2009.
IF=53.486. Rank in category: Medicine ,General & Internal=1/153
8. Mirelman A., Gurevich T., Giladi N., Bar-Shira A., Orr-Urtreger A., Hausdorff JM.
Gait Alterations in Healthy Carriers of the LRRK2 G2019S Mutation.
Ann Neurol. 2011 Jan;69(1):193-7.
IF= 10.746. Rank in category: Clinical Neurology =2/185, Neurosciences = 9/239
9. Kedmi M., Bar-Shira A., Gurevich T., Giladi N., Orr-Urtreger A.
Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease.
Molecular Neurodegeneration 2011 Sep 23;6:66.
10. Thaler A, Mirelman A, Gurevich T, Simon E, Orr-Urtreger A, Marder K, Bressman S, Giladi N; LRRK2 Ashkenazi Jewish Consortium
Lower cognitive performance in healthy G2019S LRRK2 mutation carriers.
Neurology 2012 Sep 4;79(10):1027-32
11. Van Nuenen BF, Helmich RC, Ferraye M, Thaler A, Hendler T, Orr-Urtreger A, Mirelman A, Bressman S, Marder KS, Giladi N, van de Warrenburg BP, Bloem BR, Toni I; on behalf of the LRRK2 Ashkenazi Jewish Consortium.
Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
Brain. 2012 Dec;135(Pt 12):3687-3698.
12. Kenny EE, Pe'er I, Karban A, Ozelius L, Mitchell AA, Ng SM, Erazo M, Ostrer H, Abraham C, Abreu MT, Atzmon G, Barzilai N, Brant SR, Bressman S, Burns ER, Chowers Y, Clark LN, Darvasi A, Doheny D, Duerr RH, Eliakim R, Giladi N, Gregersen PK, Hakonarson H, Jones MR, Marder K, McGovern DP, Mulle J, Orr-Urtreger A, Proctor DD, Pulver A, Rotter JI, Silverberg MS, Ullman T, Warren ST, Waterman M, Zhang W, Bergman A, Mayer L, Katz S, Desnick RJ, Cho JH, Peter I.
A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci.
PLoS Genet. 2012;8(3):e1002559.
13. Thaler A, Mirelman A, Helmich RC, van Nuenen BF, Rosenberg-Katz K, Gurevich T, Orr-Urtreger A, Marder K, Bressman S, Bloem BR, Giladi N, Hendler T; the LRRK2 Ashkenazi Jewish consortium.
Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
Cortex. 2013 Jan 7. pii: S0010-9452(12)00374-7.
Gait:
14. N. Giladi, J. Tal, T. Azulay, O. Rascol, DJ. Brooks, E. Melamed, W. Oertel, WH. Poewe, F. Stocchi, E. Tolosa
Validation of the Freezing of Gait Questionnaire in patients with Parkinson’s disease.
Mov Disord 24(5) :655-61;2009.
IF= 4.480. Rank in category: Clinical Neurology= 27/185
15. Weiss A., Sharifi S., Plotnik M., Van Vugt J.P.P., Giladi N. and Hausdorff J.M.
Toward Automated, At-Home Assessment of Mobility among Patients with Parkinson’s Disease, Using a Body-Worn Accelerometer.
Journal of Neurorehabilitation and Neural Repair, 2011 Nov-Dec;25(9):810-8.
IF=3.772 Rank in category: Rehabilitation= 1/44, Clinical Neurology=37/185
16. A. Mirelman, T. Herman, M. Brozgol, M. Dorfman, E. Sprecher, A. Schweiger, N. Giladi, JM. Hausdorff.
Executive function and falls in older adults: new findings from a five-year prospective study link fall risk to cognition.
PLoS One. 2012;7(6):e40297
17. Yogev-Seligmann G, Hausdorff JM, Giladi N.
Do we always prioritize balance when walking? Towards an integrated model of task prioritization.
Mov Disord. 2012 May;27(6):765-70
Epidemiology:
18. Inzelberg R., Rabey JM., Melamed E., Djaldetti R., Reches A., Badarny S., Hassin-Baer S., Cohen O., Trau H., Aharon-Peretz J., Milo R., Schwartz M., Huberman M., Gilead L., Barchana M., Liphshiz I., Fitzer-Attas C., Giladi N.
High prevalence of malignant melanoma in Israeli patients with Parkinson’s disease.
J Neural Transm. 2011 Aug;118(8):1199-207.
IF= 2.597. Rank in category: Clinical Neurology =73/185, Neurosciences = 132/239
19. Chillag-Talmor O., Giladi N., Linn S., Gurevich T., El-Ad B., Silverman B., Friedman N., Peretz C.
Use of a Refined Drug Tracer Algorithm to Estimate Prevalence and Incidence of Parkinson’s Disease in a Large Israeli Population.
Journal of Parkinson’s Disease. 2011 May; 1(1): 35–47.
20. Chillag-Talmor O, Giladi N, Linn S, Gurevich T, El-Ad B, Silverman B, Friedman N, Peretz C.
Estimation of Parkinson's disease survival in Israeli men and women, using health maintenance organization pharmacy data in a unique approach.
J Neurol. 2013 Jan;260(1):62-70
Recent cmpetitive grants:
Year
|
Name of Project
|
Source of grant
|
2009-2011
|
Decoding the genetic background of Parkinson’s Disease (Co- Investigator)
|
The Israel Science Foundation(ISF)
|
2009-2013
|
FMRI of first degree relatives of patients with PD carrying the LRRK2 G2019S mutation (PI)
|
Radboud University, Nijmegen, Netherland
|
2009-2012
|
Mutations in the LRRK2 gene among Ashkenazi Jews, consortium with Columbia University and Beth Israel Medical Center in New York (Co-PI)
|
Michael J Fox Foundation, USA
|
2010-2012
|
White matter changes in patients with Parkinson's disease (Co- PI)
|
Michael J Fox Foundation, USA
|
2010-2012
|
Ambulatory monitoring of near falls: A novel measure of fall risk (Co-Investigator)
|
National Institute of Health, USA
|
2012-2013
|
A prospective study to determine the relationships between cognitive function, gait and fall risk.
|
Israel Chief Scientist
|
2010-2012
|
DAT SPECT of PD patients and their first degree relatives (PI)
|
Michael J Fox Foundation, USA
|
2011-2015
|
The Parkinson’s Disease, Ashkenazi Jews and LRRK2
Consortium – a longitudinal extension (Co-PI)
|
Michael J Fox Foundation, USA
|
2011-2013
|
fMRI of First degree relatives of LRRK2 positive PD patients (PI)
|
Michael J Fox Foundation, USA
|
2011-2014
|
Wireless Insole for Independent and Safe Elderly Living (Co-PI)
|
European Union 7th Framework Program
|
2011-2015
|
Virtual reality-Treadmill combined Intervention for enhancing Mobility and reducing falls in the Elderly (Co-PI)
|
European Union 7th Framework Program
|
2011-2014
|
Closed-loop system for personalized and at-home rehabilitation of people with Parkinson's Disease, CUPID (Co- PI)
|
European Union 7th Framework Program
|
2013-2018
|
NPF Center of Excellence, Support Care and Outreach (PI)
|
National Parkinson Foundation, USA
|
2013
|
PPMI – Biological Markers in Asymptomatic carriers of G2019s mutations in the LRRK2 gene (PI)
|
Michael J Fox Foundation, USA
|